Giuseppe Curigliano, President Elect of ESMO and Member of the Editorial Board at OncoDaily, shared a post on X about a paper he co-authored published on Nature Medicine.
“The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care.”
Title: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Authors: Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, Sara Lonardi, Simone Scagnoli, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Antonio Ascierto, Giovanni Blandino, Giulia D’Amati, Massimo Aglietta, Chiara Cremolini, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Andrea Botticelli
Read further on Nature Medicine.
More posts featuring Giuseppe Curigliano on OncoDaily.